Slow diffusion of lactose out of galectin-3 crystals monitored by X-ray crystallography: possible implications for ligand-exchange protocols
about
A structural study of the interaction between the Dr haemagglutinin DraE and derivatives of chloramphenicolProtein Flexibility and Conformational Entropy in Ligand Design Targeting the Carbohydrate Recognition Domain of Galectin-3Structural Basis for Distinct Binding Properties of the Human Galectins to Thomsen-Friedenreich AntigenThe Carbohydrate-Binding Site in Galectin-3 Is Preorganized To Recognize a Sugarlike Framework of Oxygens: Ultra-High-Resolution Structures and Water DynamicsTaloside inhibitors of galectin-1 and galectin-3Investigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitorsThe water network in galectin-3 ligand binding site guides inhibitor designGalectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan RecognitionHuman galectin-2 interacts with carbohydrates and peptides non-classically: new insight from X-ray crystallography and hemagglutinationA linear relationship between crystal size and fragment binding time observed crystallographically: implications for fragment library screening using acoustic droplet ejection.Hydrodynamic properties of human adhesion/growth-regulatory galectins studied by fluorescence correlation spectroscopyDynamics of galectin-3 in the nucleus and cytoplasm.Quantitative proteomics reveal the anti-tumour mechanism of the carbohydrate recognition domain of Galectin-3 in Hepatocellular carcinoma.Protein crystallography and fragment-based drug design.Structural Basis Underlying the Binding Preference of Human Galectins-1, -3 and -7 for Galβ1-3/4GlcNAc.Perdeuteration, crystallization, data collection and comparison of five neutron diffraction data sets of complexes of human galectin-3CGalectin-3 as a Potential Target to Prevent Cancer Metastasis.Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors.Crystallization of Galectin-8 Linker Reveals Intricate Relationship between the N-terminal Tail and the Linker.Potential directions for drug development against galectin-7 in cancer.Structure-based rationale for differential recognition of lacto- and neolacto- series glycosphingolipids by the N-terminal domain of human galectin-8Progress in rational methods of cryoprotection in macromolecular crystallography.Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138.Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding.Crystallization of a human galectin-3 variant with two ordered segments in the shortened N-terminal tail.
P2860
Q27655587-828F705B-F004-41C4-8C36-FFF23352DF95Q27664681-189E4DB3-4453-4477-9122-E7CABFD421B5Q27674521-694B9755-0800-4969-8605-E386D0785F39Q27675776-E726DD38-830A-4C62-846E-675E8C64F734Q27675919-1E100734-7FA7-465B-806F-BAA08C380420Q27685236-A0410AB3-F45D-4D1B-8E37-F93E63DAD4F7Q27697923-05C60299-8736-44CF-8A7B-E56AF3A56AB0Q27714964-6284D227-5BD3-413D-BCFE-59BFC9E5D050Q27727738-BC6D4BE6-F311-4C90-BDE5-4A553133D381Q30435246-82AB3FF3-7B61-4555-8068-5EC346A94F41Q33605492-8F42A9D4-1CEA-4D58-992F-19CD2650702BQ33625906-467F8164-02AE-4217-ABE3-D9490146A969Q33899239-33F2C620-4E07-489C-8513-DEF04C0E1D4CQ34353117-1E4D9F09-3B42-4A3A-88DE-200FB6E74D98Q35577482-BA5F8658-369B-4CB4-8B87-DA1B8A1D15D1Q36191511-D86CEB51-32B6-4090-8E00-E38862079D16Q36326176-96E797AA-4584-44F8-9CC6-F0E6BF07E886Q37096426-0B8126BA-FC5A-4956-ADBC-1E893AECA728Q37534804-AA914DFC-1003-4ED3-8337-9C0DCF1CE4FEQ38089199-20C73A31-B400-4EF8-BFC3-41F7D3FA719AQ39611944-B2F0137D-A8B5-4E1A-A895-C1C5AA40AB83Q39968519-5BF40146-453C-41FA-BE78-33CAB16B92ADQ49447471-AD47AE80-C0EB-429C-9DE0-28D7FE993343Q52732456-F7CEDB3A-80D1-4AD7-88A9-48FC21DA8995Q55516081-CD560D89-358E-46F5-BDD8-2A38E5A55A86
P2860
Slow diffusion of lactose out of galectin-3 crystals monitored by X-ray crystallography: possible implications for ligand-exchange protocols
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Slow diffusion of lactose out ...... for ligand-exchange protocols
@ast
Slow diffusion of lactose out ...... for ligand-exchange protocols
@en
Slow diffusion of lactose out ...... for ligand-exchange protocols
@nl
type
label
Slow diffusion of lactose out ...... for ligand-exchange protocols
@ast
Slow diffusion of lactose out ...... for ligand-exchange protocols
@en
Slow diffusion of lactose out ...... for ligand-exchange protocols
@nl
prefLabel
Slow diffusion of lactose out ...... for ligand-exchange protocols
@ast
Slow diffusion of lactose out ...... for ligand-exchange protocols
@en
Slow diffusion of lactose out ...... for ligand-exchange protocols
@nl
P3181
P1476
Slow diffusion of lactose out ...... for ligand-exchange protocols
@en
P2093
Kazuya I P J Hidari
P304
P3181
P356
10.1107/S090744490605270X
P577
2007-02-21T00:00:00Z